company background image
39K logo

Centogene DB:39K Stock Report

Last Price

€0.32

Market Cap

€9.8m

7D

-10.1%

1Y

-60.2%

Updated

21 May, 2024

Data

Company Financials +

39K Stock Overview

Engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific.

39K fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Centogene N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Centogene
Historical stock prices
Current Share PriceUS$0.32
52 Week HighUS$1.44
52 Week LowUS$0.32
Beta-0.67
1 Month Change-27.36%
3 Month Change-61.81%
1 Year Change-60.20%
3 Year Change-96.17%
5 Year Changen/a
Change since IPO-97.51%

Recent News & Updates

Recent updates

Shareholder Returns

39KDE HealthcareDE Market
7D-10.1%-1.4%-0.3%
1Y-60.2%-0.9%4.5%

Return vs Industry: 39K underperformed the German Healthcare industry which returned -0.9% over the past year.

Return vs Market: 39K underperformed the German Market which returned 4.5% over the past year.

Price Volatility

Is 39K's price volatile compared to industry and market?
39K volatility
39K Average Weekly Movement17.2%
Healthcare Industry Average Movement6.0%
Market Average Movement5.0%
10% most volatile stocks in DE Market10.3%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 39K's share price has been volatile over the past 3 months.

Volatility Over Time: 39K's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2006444Kim Strattonwww.centogene.com

Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics.

Centogene N.V. Fundamentals Summary

How do Centogene's earnings and revenue compare to its market cap?
39K fundamental statistics
Market cap€9.76m
Earnings (TTM)-€40.09m
Revenue (TTM)€50.71m

0.2x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
39K income statement (TTM)
Revenue€50.71m
Cost of Revenue€30.25m
Gross Profit€20.46m
Other Expenses€60.55m
Earnings-€40.09m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.44
Gross Margin40.35%
Net Profit Margin-79.06%
Debt/Equity Ratio-289.9%

How did 39K perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.